The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2025 | The potential of CELMoDs for the treatment of multiple myeloma
In this video, Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, briefly comments on the potential of cereblon E3 ligase modulators (CELMoDs) for the treatment of multiple myeloma (MM), highlighting their superior immune activation capability and potent anti-myeloma effects compared to previous immunomodulatory drugs (IMiDs). Prof. Lonial expresses hope that the results of Phase III trials investigating iberdomide and melflufen will demonstrate their efficacy, potentially leading to increased use of these agents. This interview took place at the 11th World Congress on Controversies in Multiple Myeloma (COMy) congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
CELMoDs are, I think, a really exciting new development in myeloma because they represent a step forward from the design and function of the previous class of IMiDs like lenalidomide or pomalidomide. What I think they offer is much more effective immune activation, so they become perfect partners for this immune revolution we’re seeing in myeloma. I think it also allows us to get a more potent anti-myeloma effect through their binding affinity and changes in conformation...
CELMoDs are, I think, a really exciting new development in myeloma because they represent a step forward from the design and function of the previous class of IMiDs like lenalidomide or pomalidomide. What I think they offer is much more effective immune activation, so they become perfect partners for this immune revolution we’re seeing in myeloma. I think it also allows us to get a more potent anti-myeloma effect through their binding affinity and changes in conformation. I’m hopeful that in the next 12 to 18 months we’ll see data both for iberdomide and melflufen in Phase III trials that suggest they’re better than available therapy. This will hopefully open the door for us to use these new agents more frequently.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
